Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice Chii Chii ChewSalby NgIgnacio Segarra PRECLINICAL STUDIES 11 March 2017 Pages: 399 - 411
Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft Nataly TarasenkoAbraham NudelmanAda Rephaeli PRECLINICAL STUDIES 17 March 2017 Pages: 412 - 426
MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells Yi-Yen YehJing-Ping LiouHuei-Mei Huang PRECLINICAL STUDIES 27 March 2017 Pages: 427 - 435
Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients Valentine HeidelbergerFrançois GoldwasserSélim Aractingi PRECLINICAL STUDIES 10 April 2017 Pages: 436 - 441
Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors Patricia M. LoRussoMrinal GounderE. Gabriela Chiorean PHASE I STUDIES 04 February 2017 Pages: 442 - 450
Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study Hideo SakaChiyoe KitagawaYasuhide Yamada PHASE I STUDIES Open access 10 January 2017 Pages: 451 - 462
A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations Jianming XuYingxin LiRuihua Xu PHASE I STUDIES 19 January 2017 Pages: 463 - 470
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule Antonio JimenoManish R. SharmaMark J. Ratain PHASE I STUDIES 20 January 2017 Pages: 471 - 477
Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II C.M. NijenhuisL. LucasJ.H. Beijnen PHASE I STUDIES 31 January 2017 Pages: 478 - 490
Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS Emily ChanLaura W. GoffJordan D. Berlin PHASE II STUDIES 28 March 2017 Pages: 491 - 498
Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors Tetsuhide ItoYoshitaka HonmaAkira Shimatsu PHASE II STUDIES Open access 03 May 2017 Pages: 499 - 508
Lung cancer and β-glucans: review of potential therapeutic applications Raheleh RoudiShahla Roudbar MohammadiMonireh Mohsenzadegan REVIEW 16 March 2017 Pages: 509 - 517
Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis Giandomenico RovielloChiara PacificoDaniele Generali REVIEW 11 March 2017 Pages: 518 - 523
Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertib Andrea NecchiGiulia PintarelliFrancesca Colombo SHORT REPORT 03 February 2017 Pages: 524 - 528
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer Hisato KawakamiJunko TanizakiKazuhiko Nakagawa SHORT REPORT 20 March 2017 Pages: 529 - 536
Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients Valentine HeidelbergerFrançois GoldwasserSélim Aractingi Erratum 09 June 2017 Pages: 537 - 537